To supply tumor tissues with nutrients and oxygen, endothelial progenitor cells (EPCs) home to tumor sites and contribute to neovascularization. Although the precise mechanism of EPCs-induced neovascularization remains poorly understood in nonsmall cell lung cancer (NSCLC), histone deacetylase 7 (HDAC7) is considered as a critical regulator. To explore the function of HDAC7 in neovascularization induced by EPCs, tube formation assay, immunofluorescence, microarray, Western blot analysis and animal models were performed. In vitro, HDAC7 abrogation led to the activation of Rho-associated coiled-coil containing protein kinase/myosin light chain 2 pathway concomitant with ERK dephosphorylation, causing the instability of cytoskeleton and collapse of tube formation. In vivo, absence of HDAC7 impaired the vascular lumen integrity and decreased the functional blood perfusion, inhibiting the growth of tumor. At the level of transcription, HDAC7 silencing upregulated antiangiogenic genes and suppressed proangiogenic genes collectively, turning off the angiogenic switch during vessel formation. Taken together, HDAC7 plays a dual role in maintaining the structural and nonstructural functions of EPCs. Our work demonstrates the molecular mechanism by which HDAC7 contributes to the angiogenic property of EPCs and provides a rational basis for specific targeting of antiangiogenic strategies in lung cancer.
Introduction
A key step for malignant tumor growth, progression and metastasis is the formation of new blood vasculature. 1 Cancer development is largely dependent on tumor vascularity, whereby new vessel formation ensures an adequate supply of growth factors, nutrients, oxygen to tumor growth and dissemination. Once tumor-associated vasculature has been activated, tumors exhibit diverse patterns of neovascularization: vasculogenic mimicry (VM), mosaic vessels and endothelium-dependent vessels. 2 During the stage of tumor growth, endothelium-dependent vessels will gradually replace VM and mosaic vessels to become the dominant blood supply pattern. 2 It is widely accepted that both angiogenesis and vasculogenesis are involved in endotheliumdependent vascularization of tumor microcirculation. Angiogenesis is the expansion and remodeling of the preexisting blood vessel network, and vasculogenesis is the process that vessels are formed from bone marrow-derived endothelial precursor. Recent findings that endothelial precursor cells can migrate to sites of neovascularization deepen our understanding of postnatal vasculogenesis. 3 Accumulating data from the last decade suggest that progenitor cell is highly orchestrated under the specific tumor microenvironment for its central role in tumor vessel formation. 4 Endothelial progenitor cell (EPC) is a subtype of precursor cells with high proliferative potential that is capable of differentiating into mature endothelial cell (EC). 5 The first description of putative progenitor ECs for angiogenesis was published in 1997. 6 Subsequently, extensive research in EPCs-associated neovascularization has been described in vitro and in vivo, therapeutic effect of EPCs is also observed in the rodent models of ischemic disorders and tumors. [7] [8] [9] The biological significance of EPCs has received considerable attention for its potential value in pro-or anti-angiogenic therapy. Especially in tumor diseases, alternative antiangiogenic strategy need to be explored because of treatment resistance. 10 Further investigations reveal that circulating EPCs are recruited to the lesions in response to specific tumor-secreted cytokines, leading to the generation of new vessels in tumor. 2, 11 In addition to the physical contribution to neovascularization, that EPCs release proangiogenic cytokines may be the supportive evidence in maintenance of vascular homeostasis. 12, 13 These results indicate that EPCs have a dual role in providing both structural (vessel incorporation and stabilization) and non-structural (release of proangiogenic cytokines) functions to initiate neovascularization in tumor.
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Histone deacetylases (HDACs) regulate the dynamics of chromatin structure and gene expression through catalysis of acetyl removal.
14 Inhibition of HDACs has been confirmed not only to block postnatal vessel formation in animal models but also to downregulate the expression of typical EC genes such as endothelial nitric oxide synthase (eNOS), endothelial growth factor receptor (EGFR)-2 and vascular endothelial cadherin (VECadherin). 15 It should be noted that histone deacetylase 7 (HDAC7), a member of Class IIa HDACs (HDAC4, 25, 27 and 29), acts as a key transcriptional modulator of various development and differentiation processes. 16 Inactivation of HDAC7 results in embryonic lethality due to a failure in EC-cell adhesion and consequent dilatation and rupture of blood vessels. 17, 18 In contrast, phosphorylation of HDAC7 serves as a molecular switch to mediate vascular endothelial growth factor (VEGF) signaling and endothelial function. 19 Furthermore, previous studies of endothelium-dependent angiogenesis have emphasized that HDAC7 controls the key steps of structural and non-structural functions in mature ECs, not only for its essential role in migration, tube formation and lumen integrity but also because of its regulation of angiogenic genes and growth factors. The impact of HDAC7 deficiency on endothelial functions has indicated that loss of HDAC7 inhibits ECs migration and their capacity to form capillary tube-like structures. 19, 20 Activation of HDAC7 is required for controlling microvessel sprouting and maintaining vascular integrity in vitro and in vivo. 21 Moreover, HDAC7 is also a crucial modulator of angiogenesis by altering expression of angiogenesis-associated genes in ECs, such as upregulation of VEGF-induced proangiogenic genes and downregulation of angiogenesis suppressor gene AKAP12. 19, 22 According to the angiogenic property of EPCs and the key role of HDAC7 in ECs, we hypothesize that activation of HDAC7 is indispensable for the EPCs-induced neovascularization.
As the leading cause of cancer-related death worldwide, benefit of antiangiogenic therapy is limited in lung cancer patients. Hilbe et al. showed for the first time that an increasing number of CD133-positive EPCs could be found in non-small cell lung cancer (NSCLC) tissues and these cells seemed to contribute to the formation of capillaries. 23 Almost the same time, Dome et al. found that the higher pretreatment circulating EPC numbers correlated with a poorer overall survival in NSCLC. 24 Despite the general importance of EPCs in neovascularization, their precise role has remained controversial. A further understanding of the molecular interaction underlying EPCs function is critical for the development of antiangiogenic strategies. Therefore, the aim of our study is to determine the role and mechanism of EPCs-associated postnatal vasculogenesis in NSCLC. Here, we demonstrate that EPCs home to the tumor bed and incorporate luminally into a subset of sprouting neovessels. HDAC7 deficiency abrogates the capacity of tube formation and turns off the angiogenic switch, leading to a delay in tumor growth with distinct vascular defects.
Materials and Methods

Patients and blood samples
To measure the number of circulating EPCs at the time of diagnosis in lung cancer, healthy volunteers (n 5 5) and patients with histologically proven NSCLC (n 5 24) were enrolled before operation or alternative anti-cancer treatment. 
EPCs isolation and characterization and lentiviral infection
To obtain EPC-enriched population, mononuclear cells were isolated and characterized as described previously. 25 Cells were collected after 1, 2 and 3 weeks and eight passages, then labeled as described above and analyzed by flow cytometry with 10,000 events stored. Lentivirus vector containing HDAC7 shRNA and EGFP were purchased from GeneChem Company (Shanghai, China). Cultured cells within six passages were regarded as EPCs and infected by lentivirus at MOI 20 according to the manufacture's instruments. The HDCA7-siRNA sequence is TCACTGACCTCGCCTTCAA and the nonspecific random siRNA as the negative control and the sequence is TTCTCCGAACGTGTCACGT.
Cell culture
Isolated EPCs were cultured in endothelial basal medium 2 supplemented with EGM-2 MV Single-Quots (EGM-2 MV medium, Lonza). Human lung adenocarcinoma cell lines H1975 and H460 were characterized by Genetic Testing Biotechnology Corporation (Suzhou, China) using short tandem repeat markers and cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum at 378C in a humidified 5% CO 2 atmosphere.
Xenograft models of NSCLC
All animal experiments were approved by and conformed to the relevant regulatory standards of the Ethical Committee of HUST. Four-week-old male BALB/c nu/nu mice were housed under pathogen-free condition according to the animal care guideline. In medium, 5 3 10 6 H1975 cells or H460 cells were suspended and subcutaneously injected in the right hindlimb of mice. When xenografts developed successfully and their volume reached 30 mm 3 approximately, these tumor-bearing mice were randomly subdivided into four groups and injected with corresponding cells: EPC group (tail vein injection of 3 3 10 6 uninfected EPCs), HDAC7 negative control (NC) group (tail vein injection of 3 3 10 6 HDAC7 NC EPCs), HDAC7 knockdown (KD) group (tail vein injection of 3 3 10 6 HDAC7 KD EPCs) and SAHA treatment group (tail vein injection of 3 3 10 6 HDAC7 NC EPCs and intraperitoneal injection of suberoylanilide hydroxamic acid (SAHA)). SAHA (Sigma) was dissolved in dimethyl sulfoxide (DMSO) (50 mg/ml) and diluted with a mixture of polyethylene glycol 300 and sterile saline, resulting a working solution (2.5 mg/ml, containing 5% DMSO) before intraperitoneal injection (50 mg/kg) for consecutive 10 days. To trace EPC population in vivo, all cells were labeled with near-infrared fluorescent dye 3,3,3 0 ,3 0 -tetramethylindotricarbocyanine iodide (DiR) (Ex/Em 750/790 nm, 2 lmol/l) at 378C for 15 min before EPCs transplantation. After 10 days, In Vivo Fluorescence Imaging (Bruker, Germany), Doppler ultrasonography (Philips) and confocal laser endomicroscope (Cellvizio, France) were used to assess the distribution and perfusion of microvasculatures in tumor, and the incorporation of EPCs in neovessels stained with CD31 (Boster, China), respectively. All mice were killed and tumors were removed for the further analysis.
Microarray data
GeneChip PrimeView human gene expression array was carried out following the standard Affymetrix protocol. The data discussed in this publication have been deposited in the NCBI's Gene Expression Omnibus (GSE102178).
Tube formation assay, immunohistochemistry, immunofluorescence, real-time PCR analysis and Western blot analysis
Experiments were carried out as described in the Supporting Information for Materials and Methods.
Statistical analysis
Data were expressed as mean 6 SD. Each value is the mean of at least three separate experiments in each group. The statistical significance between groups was determined by Student's t test or one-way analysis of variance using GraphPad Prism 6.0 software (GraphPad Software Inc., USA). p < 0.05 was considered as a statistically significant difference.
Results
Number of circulating EPCs increases in NSCLC patients and correlates with the stage of disease
To investigate the role of EPCs in NSCLC progression, the number of circulating EPCs was assessed in five healthy controls and 24 NSCLC first-visit patients (Supporting Information Table S1 ). EPCs were determined as CD34 
HDAC7 is required for the tube formation of EPCs in vitro
These isolated cells were characterized with the distinctive cobblestone-like colonies, binding to lectin, uptake of ac-LDL, and positive expression of mature EC markers, which were consistent with the typical morphology, functions and surface molecules of EPCs (Supporting Information Fig. S1 ). To verify the role of HDAC7, the validation after HDAC7 knockdown was confirmed first (Fig. 2a) . Then, we found that deletion of HDAC7 resulted in the rupture of capillary-like networks (Fig.  2b) . Statistical analysis further suggested that it was the reduction in tubule number and total tubule area, rather than in the number of junctions, branches and total length that led to the collapse of capillary structure (Fig. 2c) . These observations indicate collectively that HDAC7 is required specifically for maintaining the capacity of EPCs to form capillary tube-like structure.
HDAC7 deficiency impedes EPCs-associated neovascularization in vivo
NSCLC xenograft models were established in nude mice to explore the EPCs-associated vessel formation. In KD and SAHA (a pan-HDACs inhibitor) groups, the development of tumors was significantly suppressed on 10th day with the smaller tumor size and lower tumor weight (Fig. 3a) . To trace the DiR-labeled EPCs after transplantation, in vivo imaging was used to monitor the distribution of EPCs. A significantly lower fluorescence intensity of tumor sites in KD and SAHA groups indicated the reduced recruitment of EPCs compared with the normal EPC and NC groups (Fig.  3b, arrows) . Similar result was reduplicated in these isolated tumors which were removed from the mice (Fig. 3c) . Given the necessity of functional vessels in tumor progression, blood perfusion of tumors was detected by Doppler ultrasonography. As shown in Figure 3d , fewer blood flow signals and larger necrotic area suggested that loss of HDAC7 could weaken the angiogenic property of EPCs in KD group, leading to the reduction in perfusion.
Based on the decrease in recruitment and perfusion, it was hypothesized that HDAC7 might be involved in the construction and maintenance of neovascularization induced by EPCs. Cellvizio provided an insight into the structure of tumor vessels through the measurement of functional capillary density-area (FCD-A) and FCD-length (FCD-L) in vivo. Significant reduction in FCD-A was detected in KD and SAHA groups, whereas no difference was found in FCD-L among all groups (Fig. 3e) . These data indicated that HDAC7 played a critical role in functional vessel formation, especially in stabilizing vascular integrity to provide a structural support for blood perfusion. In addition, tumor sections were isolated and immunostained with EC-specific marker CD31 to exam the microvessel density (MVD). The numbers of mircovessels were decreased significantly in KD and SAHA groups, and the analysis of MVD offered further proof that HDAC7 participated in neovascularization mediated by EPCs (Fig. 3f) . In contrast to KD and SAHA groups, in which the vessel lumens were closed and fragmentary, the vast majority of vessel lumens were open and integrated in uninfected EPC group and NC group. To verify whether EPCs incorporate directly into vessel lumens for vascular integrity, above results were reconfirmed by immunofluorescence. Notably, uninfected EPCs and NC EPCs infiltrated around the tumor vessels and incorporated into lumens, whereas few EPCs merged into vessels after HDAC7 silencing (Fig. 3g) .
Taken together, these results support that HDAC7 plays an essential role in recruitment of EPCs and in maintenance of vascular integrity.
HDAC7 controls cytoskeleton dynamics in EPCs via ROCK/MLC2 pathway
Despite its key role in vessel formation, the exact function of HDAC7 to stabilize vessel lumens remains unclear in EPCsbased neovascularization. To investigate the precise molecular mechanisms underlying HDAC7-associated angiogenic phenotype in NSCLC, we focused on the cytoskeleton remodeling in EPCs.
The excessive polymerization of actin stress fibers after HDAC7 silencing consolidated the hypothesis (Fig. 4a) , and prompted us to assess the possibility that HDAC7 controlled tubulogenesis by regulating cytoskeleton rearrangement in EPCs. Based on previous research, the increased contractile actin bundles reflect that small GTPase RhoA is activated. 21 Therefore, we further examined the expression of the RhoAassociated kinase Rho-associated coiled-coil containing protein kinase (ROCK) and the phosphorylation of its substrate myosin light chain 2 (MLC2), which correlated with the increase in stress fibers formation and actomyosin contractility. As expected, HDAC7 deficiency led to a higher expression of ROCK and phosphorylation of MLC2 compared with the controls (Fig. 4b) . Conversely, inhibiting ROCK activity with Y27632 (a ROCK inhibitor) restored proper actin polymerization in HDAC7 KD cells, as well as the capacity of tube formation (Figs. 4c and 4d) . Altogether, these data indicate that HDAC7 silencing may be responsible for the excessive actin polymerization through activation of ROCK/MLC2 pathway, leading to the increased cell contractility and vascular defects.
HDAC7 activates ERK signaling which opposes Rho-kinase to promote tube formation
Both PI3K/AKT/mTOR pathway and ERK/MAPK pathway have been reported to participate in ECs-associated angiogenesis. 26, 27 In our study, hyperphosphorylation of AKT and dephosphorylation of ERK was observed in HDAC7 KD cells (Fig. 5a ). While the further study showed that PI3K/AKT/ mTOR pathway, which was connected with angiogenesis for its regulatory effect on proangiogenic factors secretion, 28 was inactivated after HDAC7 silencing (Supporting Information  Fig. S2) .
Inhibition of ERK/MAPK signaling has also been reported to be responsible for the retraction of sprouting tubules in ECs and the inhibitory effects could be rescued by suppressing Rhokinase activity. 27 Supporting the previous article, we found that after HDAC7 silencing, the phosphorylation of ERK was attenuated concomitant with the hyperphosphorylation of MLC2, and this process could be reversed by suppressing Rho-kinase with Y27632 (Fig. 5b) . More importantly, to confirm the activation of MLC2 is associated with the ERK signaling, NC EPCs were treated with ERK inhibitor U0126 to test the phosphorylation of ERK and MLC2. Consistent results that the phosphorylation of ERK was repressed significantly with consequent hyperphosphorylation of MLC2 were observed, indicating the opposite role of ERK signaling. In addition, NC EPCs treated with U0126 reduplicated all the phenotypes of excessive actin polymerization which were found in EPCs lacking HDAC7, such as the increased cell contractility (Fig. 5c) , and the collapse of capillary tube-like structure (Fig. 5d) . Altogether, these data elucidate that ERK signaling is regulated by HDAC7 to exert opposite effects against ROCK/MLC2 pathway on actin polymerization, cell contractility and tube formation.
Loss of HDAC7 inhibits neovascularization by turning off the angiogenic switch
Once in peripheral blood, EPCs home in on tumor sites in response to the elevated cytokines formed under hypoxia, an active process requiring direct interaction between molecular targets expressed by EPCs and tumor tissues.
11 Therefore, the regulation of angiogenesis-associated factors is vital for EPCs to turn on the angiogenic switch during the sprouting angiogenesis and create a proangiogenic microenvironment.
11 Emerging studies have supported that EPCs contribute to vessel formation and remodeling by differentiating into mature ECs and releasing cytokines which are indispensable for neovascularization. This process is considered as the non-structural function of EPCs.
Based on that knowledge, we examined the expression of typical EC genes to confirm the function of HDAC7 in EPCs differentiation. EGFR2, VE-Cadherin and eNOS, such mature EC genes, were suppressed significantly after HDAC7 silencing (Fig. 6a) . Proangiogenic genes fibroblast growth factor 2 (FGF2), Slit-2, 29, 30 were also repressed significantly in KD cells (Fig. 6b ). In addition, the angiogenesis suppressor gene AKAP12, 22 which was under the control of HDAC7 in ECs, was upregulated in EPCs lacking HDAC7 (Fig. 6c) . As a key growth factor in angiogenesis, we examined the expression of VEGF and found a significant reduction when HDAC7 was deficient (Fig. 6d) . These results implied that loss of HDAC7 could turn the angiogenic switch toward "off" and prompted us to expand the scope of angiogenesis-associated genes after HDAC7 silencing.
To understand the role of HDAC7 comprehensively, we profiled the gene expression changes in HDAC7 KD cells by microarray. As shown in Figure 6e , bioinformatic analysis identified that 19 genes whose expression were altered after HDAC7 deletion, offering a map to evaluate the function of HDAC7 during the EPC-associated neovascularization. From beginning to end, the process that EPCs contribute to tumor neovascularization could be divided into four steps: mobilization, homing, adhesion and differentiation into mature ECs via paracrine or juxtacrine signals. Loss of HDAC7 reversed the activation of migration and adhesion, relieved the inhibition of homing slightly, and repressed part of growth factors (FGF2, hepatocyte growth factor) with an upregulation of antiangiogenic genes (tissue inhibitor of metalloproteinase [TIMPs], SERPINF1). In sum, proangiogenic genes were inhibited generally with the upregulation of antiangiogenic genes, leading to a negative overall response to neovascularization after HDAC7 silencing. These data demonstrate that HDAC7 is a critical modulator in transcription of pro-and antiangiogenic genes.
Discussion
The key findings of our research are the elucidation of the angiogenic roles of EPCs in NSCLC and the exploration of their underlying mechanism. We show that EPCs contribute to neovascularization via HDAC7-mediated cytoskeleton rearrangement and angiogenic genes transcription.
Angiogenesis-mediated progression of carcinoma in situ to lethal metastasis is the major cause of death in lung cancer patients. 31 During the tumor growth and dissemination, EPCs pass through a series of complex steps to remain activated and establish neovascularization. Supporting the connection that the circulating EPCs increase with the advanced stage of disease, similar result was confirmed again in our study. Furthermore, recent findings have suggested that the reduction in circulating EPCs after anticancer therapy indicated a better response. 32 In contrast, a higher level of EPCs before treatment has implied a higher incidence of death. 24 Thus, EPC is being considered as a surrogate biomarker for monitoring cancer progression, predicting disease-free survival as well as optimizing efficacy of antiangiogenic therapy. 8, 33 These observations strengthen the hypothesis that EPCs may be a feasible target against NSCLC neovascularization.
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Using a combination of in vitro cell biology and in vivo loss of function, our work confirmed that HDAC7 was crucial in maintaining the structural function of EPCs. HDAC7 silencing impeded the recruitment and incorporation of EPCs, reduced the density of neovessels and repressed the tumor growth in the end. Further analysis revealed that EPCs failed to form the capillary tube-like structure in the absence of HDAC7, leading to the decreased FCD-A, the area of detected vessels over the total area, which was regarded as the major cause of perfusion reduction in KD group. All these data consolidated that lack of HDAC7 impaired the vessel lumens, which was the structural foundation for blood perfusion. In addition to the necessity of HDAC7 in EPCs-induced neovascularization, similar defects of vessels have been reported in mature ECs-associated angiogenesis and embryonic vasculogenesis after HDAC7 silencing, 17, 20 indicating a key role of HDAC7 in facilitating vascular integrity from embryo to progenitor cells and mature ECs.
Research on mechanism suggested that the rupture of vessel lumens in HDAC7 KD cells was the consequence of abnormal cytoskeleton dynamics and the excessive cell contractility. Instability of cytoskeleton has been evidenced by the increased actomyosin contractility controlled by HDAC7 in ECs. 21 Our work confirmed that HDAC7 silencing gave rise to the increased cell contractility of EPCs with excessive actin polymerization, which was a result of the hyperactivation of ROCK/MLC2 pathway. ROCK inhibitor could partly restore the proper phosphorylation of MLC2 as well as the capacity of tube formation in HDAC7 deficient cells. According to Georgia's work, inhibition of ERK/ MAPK signaling in the tumor vasculature resulted in loss of bipolarity, detachment of ECs and retraction of sprouting tubules, which effects were the consequence of upregulated Rhokinase signaling. 27 Consistent results were confirmed that ERK signaling was inhibited after HDAC7 silencing, and EPCs-induced angiogenesis was regulated by ERK/MAPK signaling and ROCK/ MLC2 pathway, both of which acted through the control of actomyosin contractility in an opposite way. Although phosphorylation of AKT was activated in HDAC7 KD cells, the further analysis indicated that its effect might not exert though PI3K/ AKT/mTOR signaling. Sustained activation of AKT has been reported to induce vascular malformation and systemic vascular permeability in ECs. 35 Furthermore, recent finding has revealed a positive role of R-Ras-AKT axis in stabilization of cytoskeleton and lumenization of endothelial sprouts. 36 Research on ECs indicates the involvement of AKT-dependent pathway and the distinctive activation of AKT-dependent axis, but further work is needed to confirm the up-and downstream molecules of AKT signaling in EPCs and their exact effects on angiogenic property.
Releasing growth factors to sustain a proangiogenic microenvironment is regarded as the non-structural function of EPCs. During tumor progression, angiogenic switch remains on to elevate serum level of angiogenic growth factors, causing the sprouting neovessels and expanding tumors. 1, 37 In some NSCLC patients, metastatic spread has already occurred by the time of primary diagnosis, targeting the angiogenic switch via EPCs may provide a clinically feasible approach to block metastatic progression and prevent death. 38 The process that EPCs contribute to tumor neovascularization can be divided into four steps: mobilization from the bone marrow to the peripheral blood via expression of receptors (EGFR2, C-C chemokine receptors [CCRs] ) and integrins (b3 and a4b1); 39 homing to tumor sites in a chemotaxis response to tumor-secreted chemokines, which interact with respective receptors (EGFR2, CXC chemokine receptor [CXCR]-1, 2, 4 and CCRs) on EPC surface; 11,40-43 adhesion into tumor tissues through P-selectin glycoprotein ligand-1, integrins and selectins, which facilitate the trans-endothelial migration to cross the endothelial monolayer; 39 and differentiation into mature ECs via paracrine or juxtacrine signals.
11 As so far, very few research has shed light on the effect of HDAC7 during all above steps. Our work revealed a negative overall response to neovascularization in EPCs after HDAC7 silencing for the first time. Especially, the dramatical inhibition of genes such as hypoxia inducible factor 1 (HIF-1) and matrix metalloproteinases (MMPs), which were involved in EPCs adhesion, might be responsible for the repressed recruitment and adhesion of EPCs partly because HIF-1 is activated to upregulate the transcription of multiple adhesion-associated factors, 44 and MMPs are triggered to degrade and remodel ECM components in preparation for the selection-initiated adhesion.
11, 45 In addition, EPCs contribute to lumen formation, vessel remodeling and neovascular homeostasis via paracrine/juxtacrine signals such as VEGF, stromal cell-derived factor-1, platelet derived growth factor-1 and FGF2. 39, 46 Although the transcriptional change in these genes were not always consistent, the significant reduction in VEGF, which was a leading growth factor for EPCs, strengthened the hypothesis that lack of HDAC7 altered the proangiogenic property of EPCs negatively. VEGF has been reported to promote phosphorylation of HDAC7 in ECs, 47 our data suggested that expression of VEGF was regulated by HDAC7 in turn. Decrease in VEGF is helpful to reverse the microenvironment for neovascularization. Moreover, it should be noted that the inhibitor of MMPs encoded by TIMP genes 48 and the serpin encoded by SERPINF1 gene can strongly suppress angiogenesis. Upregulation of such angiogenic suppressor genes consolidate the central role of HDAC7 in keeping the balance of endogenous pro-and anti-angiogenic factors. Altogether, from the EPCs mobilization, homing to adhesion and secretion, HDAC7 acts as a key switch for neovascular homeostasis via altering the transcription and expression of key molecules involved in the whole angiogenic processes.
Taken all effects together, EPCs participate in tumor progression due to their ability to form new vessels and regulate angiogenic switch. Deletion of HDAC7 impairs the neovessel structure and to keep this switch in the "off" position, leading to the perfusion reduction and growth delay in NSCLC models. Our works indicate that HDAC7 can be considered as a novel antiangiogenic intervention for NSCLC.
